41,174 Amgen Inc. $AMGN Shares Sold by M&G PLC

M&G PLC lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 14.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 248,645 shares of the medical research company’s stock after selling 41,174 shares during the period. M&G PLC’s holdings in Amgen were worth $104,928,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Leuthold Group LLC lifted its position in shares of Amgen by 9.2% during the third quarter. Leuthold Group LLC now owns 22,409 shares of the medical research company’s stock worth $9,446,000 after purchasing an additional 1,897 shares during the last quarter. Fulcrum Asset Management LLP grew its stake in Amgen by 65.5% in the third quarter. Fulcrum Asset Management LLP now owns 4,428 shares of the medical research company’s stock worth $1,876,000 after purchasing an additional 1,752 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Amgen by 16.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 112,799 shares of the medical research company’s stock valued at $45,940,000 after buying an additional 16,327 shares during the last quarter. Beverly Hills Private Wealth LLC increased its holdings in Amgen by 2.6% in the third quarter. Beverly Hills Private Wealth LLC now owns 2,399 shares of the medical research company’s stock valued at $1,011,000 after buying an additional 60 shares during the last quarter. Finally, Almanack Investment Partners LLC. raised its stake in Amgen by 7.5% during the third quarter. Almanack Investment Partners LLC. now owns 2,553 shares of the medical research company’s stock valued at $1,076,000 after buying an additional 178 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on AMGN. Scotiabank increased their target price on Amgen from $500.00 to $530.00 and gave the stock a “sector outperform” rating in a report on Wednesday, November 4th. Robert W. Baird raised their price objective on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Oppenheimer reaffirmed an “outperform” rating on shares of Amgen in a report on Friday, October 23rd. Cantor Fitzgerald raised their price target on shares of Amgen from $440.00 to $465.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 4th. Finally, Morgan Stanley lifted their price target on shares of Amgen from $359.00 to $410.00 and gave the company an “equal weight” rating in a report on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus price target of $422.76.

Amgen Stock Performance

Shares of AMGN opened at $465.23 on Tuesday. The firm has a fifty day moving average of $423.08 and a 200-day moving average of $378.80. The company has a market cap of $251.52 billion, a price-to-earnings ratio of 26.99, a price-to-earnings-growth ratio of 3.47 and a beta of 0.43. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.13 and a current ratio of 1.48. Amgen Inc. has a 1 year low of $312.39 and a 1 year high of $483.99.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping analysts’ consensus estimates of $5.79 by $0.66. The business had revenue of $10.37 billion for the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned $5.64 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 23.33 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is 58.47%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New AHA 2026 data reinforced Repatha’s potential: an analysis found it cost-effective for high-risk patients without a prior heart attack or stroke, while a separate long-term analysis associated treatment with a 29% lower risk of major cardiovascular events in patients with ASCVD. The findings could support wider use, though the reported analyses do not guarantee future sales growth. Article: New Repatha data at AHA 2026
• Positive Sentiment: Amgen is heading into ACR week with a dazodalibep update expected November 11, creating a near-term clinical catalyst for its pipeline. The article headline does not specify the results, so the update’s impact will depend on the data. Article: Amgen stock heads into ACR week with dazodalibep update
• Positive Sentiment: An article highlighted experimental obesity drug MariTide’s potential to reduce dosing from 52 injections a year to four. If borne out in clinical development, less frequent dosing could be a competitive advantage; the drug remains experimental. Article: Amgen’s new drug could mean fewer shots for obesity patients
• Neutral Sentiment: Amgen shares rose in Monday trading but underperformed the broader market, indicating the move was not as strong as the overall market’s. Article: Amgen stock rises Monday, still underperforms market
• Negative Sentiment: ETFs were net sellers of $68.5 million of AMGN on November 5, a potential near-term supply headwind, although 51 funds bought shares and 20 sold. Article: ETFs are net sellers of Amgen

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is owned by company insiders.

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.